BOSTON ( TheStreet) -- Human Genome Sciences ( HGSI), Dendreon ( DNDN) and MELA Sciences ( MELA) each face off against regulators and independent experts next week in a series of separate meetings that will play an important determining role in the future of their respective drugs and medical devices.

The big meetings will unfold over three straight days next week, Nov. 16-18, but the action actually kicks off Friday. What follows is a day-by-day calendar to help investors interesting in following these important meetings.

Friday, Nov. 12
Stock to watch: Human Genome Sciences

The U.S. Food and Drug Administration is expected to post briefing documents for next week's advisory panel set up to review Human Genome's lupus drug Benlysta. These FDA documents will include the agency's review of the drug and the voting questions that will be posed to the panel's independent experts.

The FDA typically posts advisory panel briefing documents in the morning. You'll want to check frequently the FDA's Arthritis Drugs Advisory Committee web site starting around 7:30 am.

Traders will be keying on what the FDA says about Benlysta in its review, which will, of course, impact Human Genome Science's stock price.

Tuesday, Nov. 16
Stocks to watch: Human Genome Sciences and MELA Sciences

The FDA convenes an advisory panel to review Human Genome Science's lupus drug Benlysta, beginning at 8 am. Expect a trading halt in Human Genome all day, which may or may not extend into the after-hours trading session depending on the length of the panel meeting.

I will be live-blogging the Benlysta panel all day, including a real-time, play-by-play of the panel's votes on whether to recommend the drug's approval, which will likely come towards the mid-afternoon. A live link to my blog will be available on Tuesday morning, starting around 7:45 am ET, but you can register now for an email reminder below.

I previewed the Benlysta FDA panel on Monday, which outlines the issues and questions that will likely be raised about the drug's efficacy and safety.

Also on Tuesday, the FDA is expected to post briefing documents for the advisory panel set up to review MELA Sciences' skin cancer detection device MELAFind. Like above, these briefing documents will include the FDA's review of MELAFind and will clearly have a big impact on MELA Sciences trading.

Check the FDA's General and Plastic Surgery Devices Panel web site early Tuesday morning for the MELAFind briefing documents.

Wednesday Nov. 17
Stock to watch: Dendreon

Investor focus will shift from FDA to the Center for Medicare and Medicaid Services (CMS), which is conducting a "national coverage analysis" to determine reimbursement coverage for on-label and off-label use of Dendreon's prostate cancer vaccine Provenge.

Much has been made about Provenge's $93,000 price tag and whether that's justified for a therapy that extends survival by four months. Medicare is not supposed to factor a drug's cost into reimbursement decisions, but that won't stop Provenge's cost from being the big pink elephant in the CMS meeting room.

Dendreon isn't in any real jeopardy of losing Medicare reimbursement for Provenge. (Most of the Medicare regional carriers already pay for the therapy.) What is more likely to occur Wednesday is that CMS is seeking to limit Provenge coverage to patients with prostate cancer that fits the description in the FDA-approved label. Most analysts do not include off-label use of Provenge in their Dendreon models and estimates.

CMS panels are different than those held by FDA in that panel members are not given the opportunity to vote up or down on a drug's approval. Instead, CMS will be asking its panel members to vote on their "confidence level" to a list of questions about Provenge's efficacy and safety as it pertains to on-label and off-label use.

The list of questions for the Provenge panel can be found here on the CMS web site.

That same CMS web page includes a free registration link for a web-broadcast of the Provenge meeting.

Also, watch for CMS to release a "technical assessment" report on Provenge any day before the Nov. 17 panel. This report assesses the current Provenge clinical data, including, most importantly, the strength of the survival benefit, and is written by an independent group.

Thursday, Nov. 18
Stock to watch: MELA Sciences

The FDA advisory panel meeting for MELAFind kicks off at 8 am ET. I will be live-blogging the panel all day, so check back for a live link or register below for an email reminder:

I've been critical of MELAFInd in the past so in full disclosure, I expect Thursday's panel to be tough on the skin cancer detection device.

You can read my analysis of the MELAFind clinical data and a statistical issue that has hung over the stock. I also commented on MELA in a recent Biotech Stock Mailbag.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Stock Futures Waver as Earnings Season Begins

Stock Futures Waver as Earnings Season Begins

Stocks to Watch: WellPoint, Amerigroup, Alcoa (Update 1)

Stocks to Watch: WellPoint, Amerigroup, Alcoa (Update 1)

5 Things You Should Know Before the Stock Market Opens

5 Things You Should Know Before the Stock Market Opens

Celgene Not Buying Human Genome Sciences

Celgene Not Buying Human Genome Sciences

Human Genome Sciences Inc (HGSI): Today's Featured Health Care Winner

Human Genome Sciences Inc (HGSI): Today's Featured Health Care Winner